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Background: Since 1993, we have performed minimally invasive laparoscopic liver resection (LLR) to treat malignant
liver cancer, including colorectal liver metastases (CLM). However, further studies are needed to accumulate sufficient
evidence on the oncological outcome of LLR for CLM.
Methods: To elucidate the efficacy of LLR for CLM, this study comparatively analyzed the invasiveness and short-term
prognosis of LLR (n = 43 cases) and open liver resection (OR) (n = 62 cases) performed for CLM after 2006 and also
investigated the safety of LLR following chemotherapy.
Results: Compared with the OR group, the LLR group had significantly less blood loss (P < 0.001) and a shorter
hospital stay (P < 0.001). The E-PASS scoring system was used to compare surgical invasiveness, and although the
preoperative risk score did not differ between the groups, the surgical stress score and comprehensive risk score
were significantly lower in the LLR group (P < 0.001). Concerning the survival rate and disease-free survival rate,
there were no significant differences between procedures. However, more clinical cases and longer follow-up
periods are needed to reach a definitive conclusion.
Preoperative hemanalysis, intraoperative bleeding, complications, and postoperative length of stay did not differ
significantly between LLR patients with preoperative chemotherapy and those with surgery alone, indicating no
adverse effects of chemotherapy.
Conclusions: LLR can be an effective minimally invasive surgery in CLM patients receiving both perioperative
chemotherapy and surgery. Because LLR is comparable with OR with regard to short-term oncological outcome,
LLR may be a valuable option for CLM.
Keywords: Laparoscopic liver resection, Colorectal liver metastases, Preoperative chemotherapyBackground
With the improvement in laparoscopic techniques and
advances in surgical equipment, the safety and minimally
invasiveness of laparoscopic liver resection (LLR) have
been gaining recognition, and the procedure is on the
verge of becoming a standardized surgical procedure due
to the steadily increasing number of cases. However, no
prospective randomized controlled study has been per-
formed to compare oncological outcome between open* Correspondence: yoshihisa.kubota@med.toho-u.ac.jp
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unless otherwise stated.liver resection (OR) and LLR in cases of malignant tumor.
In 1993, several institutions including ours conducted
studies on laparoscopic partial hepatectomy of hepato-
cellular carcinoma [1]. We later performed laparoscopic
lateral hepatectomy for malignant tumors including colo-
rectal liver metastasis (CLM), and in 1996, we reported the
safety of LLR for CLM and its potential usage as a standard
surgical technique [2]. We perform LLR in compliance
with the indications, and to date, we have accumulated 211
cases of LLR, including 164 malignant cases. CLM is differ-
ent from hepatocellular carcinoma in that the liver is
otherwise normal and individual lesions are generally
curable after resection with a free surgical margin, such asLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tages include abdominal adhesion due to surgery for the
primary tumor, and more recently, hepatic damage caused
by preoperative chemotherapy [3,4]. However, no study
has investigated the effect of preoperative chemotherapy
on LLR. To elucidate the efficacy of LLR for CLM, we
therefore compared the invasiveness and short-term prog-
nosis of LLR and OR, and we evaluated the safety of LLR
and the effect of chemotherapy on LLR.
Methods
Subjects
The Institutional Review Board of the Toho University
Omori Medical Center approved this retrospective study
(25 to 240). Our institution incorporated modified FOL-
FOX6 (mFOLFOX6) therapy in 2006 and molecularly tar-
geted drugs, such as bevacizumab and cetuximab, in 2008.
Between January 2006 and January 2013, 115 patients with
CLM underwent hepatectomy, and of them, 105 were
traceable and enrolled in this study. Clinical parameters
were age, sex, primary tumor location, lymph node metas-
tasis, time of liver metastasis, size and number of tumors,
preoperative chemotherapy, intraoperative bleeding,
operative duration, postoperative complications, and
postoperative length of stay. Postoperative complications
were evaluated in accordance with the Clavien-Dindo
Classification [5], and the Estimation of Physiologic Ability
and Surgical Stress (E-PASS) scoring system [6] was used
to assess the low invasiveness of the surgical procedures.
In addition, the rates of overall survival (OS) and disease-
free survival (DFS) were compared.
To reveal the effects of preoperative chemotherapy on
hepatectomy in the LLR group, the levels of transaminase
and total bilirubin, prothrombin activity, platelet count,
and the retention rate of indocyanine green 15 minutes
after administration (ICGR15) were measured immedi-
ately before hepatectomy. Biopsy histopathology was
performed according to the study by Rubbia-Brandt
et al. [4] to elucidate hepatic damage due to chemother-
apy. Clinical parameters were analyzed using the t-test
and the Χ2 test, and OS and DFS were determined by
Kaplan-Meier survival analysis followed by the log rank
test. Statistical significance was set at P < 0.05.
Principles of treatment for colorectal liver metastases
If a decision was made to resect metachronous liver me-
tastases, the procedure was performed immediately by
hepatectomy without preoperative chemotherapy.
With regard to simultaneous liver metastasis, six cycles
of mFOLFOX6 + cetuximab or bevacizumab were given
prior to hepatectomy in the following categories of
patients: those >75 years old and those requiring >60%
resection, portal vein embolization, and emergency
surgery for conditions such as intestinal obstructionand perforation. Regardless of metachronous or simul-
taneous liver metastases, patients with an unresectable
tumor received mFOLFOX6 + cetuximab as the first-
line treatment and underwent hepatectomy as soon as
the tumor became resectable. A recurrent liver tumor
in the remnant liver was regarded as the first liver
metastasis and treated by hepatectomy if resectable.
Indications for laparoscopic liver resection and surgical
options for colorectal liver metastases
The basic principles behind the indications and treat-
ment for LLR entail the selection of cases in which LLR
can be performed without compromising the safety and
curability of patients, as in OR. Briefly, patients were
subjected to general anesthesia according to the same
protocol [7]. Preoperative liver function was evaluated
collectively based on hemanalysis results, ICGR15, and
remnant liver volume by computed tomography. If
curable radical resection was applicable, there was no
limit to the number of tumors. Although tumor size
was not a limiting factor, it was often difficult to treat
tumors larger than 8 cm. Partial resection was the
fundamental surgical procedure, but systematic hepa-
tectomy was sometimes selected depending on tumor
location. In LLR, we aimed to resect with a 10-mm
margin as long as the remnant liver remained func-
tional; however, with regard to multiple tumors or
tumors adjacent to the vascular system, the top priority
was to ensure complete resection. In addition, many of the
patients with CLM had undergone previous surgery for
colorectal cancer, colostomy, or hepatectomy for recurrent
tumor in the remnant liver. In these patients, a preopera-
tive abdominal ultrasound was useful for ‘assessing the
risk of intra-abdominal adhesions [8,9]. For the assess-
ment, a linear-type ultrasonic probe was used to evalu-
ate differences in movement on the longitudinal side of
the abdominal viscera accompanying spontaneous
respiration, and the first trocar was inserted into the
abdominal site where no adhesion was observed.
Surgical techniques
We have previously reported detailed LLR techniques
[10]. Patients with a tumor in the right lobe underwent
surgery in the left semilateral position, and those with a
tumor in the left lobe underwent surgery in the supine
position. Although the trocar sites differed according to
tumor location, an endoscopic trocar was inserted at the
umbilicus, while surgical manipulation trocars were
inserted into 2 to 4 ports. Exploration of tumor extent
and its relationship with vascular anatomy and with
other tumors in the liver were performed by intraopera-
tive ultrasonography. Laparoscopic coagulation shears
(Ethicon Endo Surgery Inc, Tokyo, Japan), a microwave
tissue coagulator, and a monopolar sealer are generally
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However, deeper transactions require careful use of
ultrasonic dissection or the clamp crushing method. In
this study, small vessels were transected by a bipolar
sealing system or by clipping. Glisson’s capsule and hep-
atic veins were transected using a stapling device.
Pure laparoscopic liver resection has become the
major procedure in systematic hepatectomy cases in
recent years. However, depending on tumor size andTable 1 Demographic and clinical data of the study patients
Parameter LLR group (n = 4












2 to 4 15
≥5 1
Perioperative chemotherapy 14 (32.6%)
Type of resection
Partial resection 25




Par, lat:seg, hmb 36:7
Operative time (min) 333.9 ± 150.3
Operative blood loss (cc) 287.3 ± 459.3
Perioperative blood transfusion 1 (2.4%)
R1 resection 0 (0.0%)
Postoperative hospital stay (days) 7.3 ± 1.8







aExcept left lateral sectionectomy; bPartial resection, left lateral sectionectomy: Segmen
LLR, laparoscopic liver resection; OR, open liver resection.location, other laparoscopy-assisted techniques can be
used. Hand-assisted laparoscopic surgery is particu-
larly useful for treating lesions in superior segments,
such as segments VII and VIII.
Results
Laparoscopic liver resection versus open liver resection
One hundred-five patients with CLM who underwent
hepatectomy at the Toho University Omori Medical3) OR group (n = 62) P value

















305.9 ± 107.1 0.149
579.3 ± 392.0 <0.001
13 (21.0%) 0.004
4 (6.5%) 0.117







tectomy, sectionectomy (except left lateral sectionectomy), hemi-hepatectomy.
Figure 1 Estimation of physiologic ability and surgical stress. Preoperative risk score (PRS): -0.0686 + 0.00345X1 + 0.323X2 + 0.205X3 + 0.153X4 +
0.148X5 + 0.0666X6; X1, age; X2, presence (1) or absence (0) of severe heart disease; X3, presence (1) or absence (0) of severe pulmonary disease; X4,
presence (1) or absence (0) of diabetes mellitus; X5, performance status index (0 to 4); X6, American Society of Anesthesiologists physiologic status
classification (1 to 5). LLR, laparoscopic liver resection; OR, open liver resection. Surgical stress score (SSS): −0.342 + 0.0139X1 + 0.092X2 + 0.352X3; X1,
blood loss/body weight (g/kg); X2, operation time (h); X3, extent of skin incision ((0) minor incision for laparoscopic or thoracoscopic surgery including
scope-assisted surgery; (1) laparotomy or thoracotomy alone; (2) both laparotomy and thoracotomy). LLR, laparoscopic liver resection; OR, open liver
resection. Comprehensive risk score (CRS): −0.328 + 0.936(PRS) +0.976(SSS). LLR, laparoscopic liver resection; OR, open liver resection.
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and OR (n = 62 cases, 59.0%) groups. There were no sig-
nificant differences in age, sex, primary tumor location,
or lymph node metastasis between the groups. In
addition, the largest tumor diameter did not differ be-
tween the groups (P = 0.094); however, the LLR group
had a significantly higher number of solitary tumors
(P = 0.008). Preoperative chemotherapy was performed
in 14 patients (32.6%) in the LLR group and in 29 pa-
tients (46.8%) in the OR group (P = 0.104). The LLR
group had a significantly higher number of partial hep-
atectomy and lateral hepatectomy cases (P < 0.001).
Intraoperative bleeding was significantly low in the
LLR group (P < 0.001), with only one case of intraoper-
ative transfusion (P < 0.01). Although the LLR group
had no cases of R1 resection, there were four cases of
R1 resection in the OR group. The prevalence of post-
operative complications did not differ between the
groups (P = 0.137). One patient in the LLR group had a
grade I prolonged fever, while the OR group had one
case of grade I intestinal obstruction, one case of gradeFigure 2 Overall survival and disease-free survival in the study groupIII biliary fistula, one case of grade III intra-abdominal
abscess, and three cases of grade II anastomotic leak-
age after simultaneous colectomy. The postoperative
length of stay was significantly shorter in the LLR
group (P < 0.001) (Table 1).
The E-PASS examination revealed a significantly lower
surgical stress score (SSS) and comprehensive risk score
(CRS), but not a preoperative risk score (PRS) (Figure 1)
in the LLR group (P < 0.001). The median observation
period was 36.8 months. The 3-year survival rate was
88.4% and 74.2% in the LLR and OR group, respectively,
with no significant differences in OS (P = 0.261) or DFS
(P = 0.053) (Figure 2). Tumor recurrence in remnant
liver occurred in 16 cases (37.2%) in the LLR group and
in 36 cases (58.1%) in the OR group. OS and DFS in the
single tumor cases did not differ between the groups
(P = 0.733 and P = 0.178, respectively) (Figure 3). In
addition, although the number of cases is small, OS and
DFS in the multiple tumor (two or more) cases have
shown no difference between the groups (P = 0.585 and
P = 0.870, respectively) (Figure 4).s. LLR, laparoscopic liver resection; OR, open liver resection.
Figure 3 Overall survival and disease-free survival in the single tumor cases. LLR, laparoscopic liver resection; OR, open liver resection.
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effect of preoperative chemotherapy
Thirty-two patients (76.1%) had a history of laparotomy
by midline abdominal incision, four patients (12.5%) had
undergone colostomy, and three patients (9.4%) had
undergone more than two laparotomies. In these patients,
preoperative abdominal ultrasound was performed to
reveal intra-abdominal adhesions and contributed to the
safe placement of the first trocar and successful comple-
tion of LLR. In the LLR group, preoperative chemotherapy
included eight cases of mFOLFOX6 + bevacizumab, four
cases of mFOLFOX6, one case of FOLFOX4 + bevacizu-
mab and one case of FOLFIRI + bevacizumab with a me-
dian chemotherapy cycle number of 7.2 ± 2.4. Among the
43 cases of laparoscopic liver resection, there were 26
cases (60.5%) of pure laparoscopic liver resection, nine
cases (20.9%) of hand-assisted laparoscopic surgery, and
eight cases (18.6%) of laparoscopy-assisted liver resection.
Repeat hepatectomy for recurrence in the remnant liver
was performed in six patients (37.5%), of whom three
underwent LLR (Table 2). The preoperative levels of trans-
aminase and total-bilirubin, prothrombin activity, platelet
count, and ICGR15 were normal, with no significant dif-
ferences between the preoperative chemotherapy and sur-
gery only groups. With regard to histological liver damage,
five patients in the preoperative chemotherapy group
had Rubbia-Brandt Classification grade 1 to 2 sinusoidal
obstructive syndrome, with no significant differences in
intraoperative bleeding, postoperative length of stay, or
postoperative complications (Table 3).Figure 4 Overall survival and disease-free survival in the multiple tumDiscussion
In general, laparoscopy is considered less invasive than
laparotomy; however, the methods of assessment vary
widely. The E-PASS scoring system is often used for the
assessment of surgical invasiveness because it collect-
ively evaluates preoperative physiological function, intra-
operative bleeding, operative duration, and incision size.
It also expresses the risk of morbidity and mortality
numerically. Although PRS did not differ between the
LLR and OR groups, SSS and CRS were significantly
lower in the LLR group. In addition, compared with the
OR group, the LLR group had no serious complications,
and the length of hospital stay was shorter, indicating
the minimal invasiveness.
Hepatectomy is currently the first treatment option for
CLM, and with a 5-year survival rate of 30 to 60%, it is
considered the only curable option [11-13]. In Japan,
partial hepatectomy has been the conventional surgical
option for liver metastasis because there are no differ-
ences in the survival or recurrence rates between partial
and systematic resection [14]. Thus, choice of surgery is
not a prognostic factor [15]. In addition, the outcome is
considered satisfactory if no tumor cells are exposed
at the resection site in the remnant liver [16,17], and
partial hepatectomy is reportedly applicable for R1
resection in patients treated in preoperative chemo-
therapy [18]. Taking these factors into consideration,
LLR appears to be a practical surgical procedure. This
is also because partial hepatectomy is the standard
surgical procedure in LLR and is considered the mostor cases. LLR, laparoscopic liver resection; OR, open liver resection.
Table 2 Characteristics of patients undergoing
laparoscopic liver resection
History of laparotomy by midline incision 32/43 (76.1%)
Colostomy 4/32 (12.5%)
More than two laparotomies 3/32 (9.4%)
Preoperative chemotherapy (n = 14)
mFOLFOX6 + bevacizumab 8
mFOLFOX6 4
FOLFOX4 + bevacizumab 1
FOLFIRI + bevacizumab 1
Median cycle number (course) 7.2 ± 2.4
Indications for preoperative chemotherapy
Received chemotherapy in other institution 7
Presence of extrahepatic metastasis 3
Large and multiple tumors 2
Emergency surgery for primary tumor 2
Surgical procedures
Pure laparoscopic liver resection 26 (60.5%)
HALS 9 (20.9%)
Laparoscopy-assisted liver resection 8 (18.6%)
Recurrence in the remnant liver 16/43 (37.2%)
Repeat hepatectomy 6/16 (37.5%)
Repeat hepatectomy underwent LLH 3/6 (50.0%)
HALS, hand assist laparoscopic surgery;
LLH, laparoscopic liver resection; mFOLFOX6, modified FOLFOX6.
Table 3 Characteristics of laparoscopic liver resection patient
surgery alone
Parameter Preoperative chemother
AST (U/l) 22.9 ± 6.6
ALT (U/l) 19.4 ± 8.9
T-Bil (mg/dl) 0.56 ± 0.13
PT (%) 103.8 ± 10.1
Plt (104/μl) 18.7 ± 5.9
ICGR15 (%) 8.2 ± 4.1
>10% 4 (28.6%)
Operative blood loss (cc) 452.1 ± 692.4






ALT, aspartate aminotransferase; AST, alanine aminotransferase; ICGR15: indocyanin
consumption test; T-Bil, total bilirubin.
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of the liver, such as segments IVa, V, and VI [11].
Although no difference in OS or DFS was observed
between the LLR and OR group in this study, the rate
of partial hepatectomy in single tumor cases, namely, a
fair prognostic factor [19], was relatively high in the
LLR group. However, the OS and DFS in single tumor
cases did not significantly differ between the LLR and
OR groups. The 5-year survival rate of LLR has been
reported to be 50% for CLM [20]. Although no
prospective randomized controlled study of LLR or OR
performed for malignant tumors has been reported,
retrospective studies have shown similar long-term
prognosis in patients treated with LLR and OR for
CLM [21,22].
The efficacy of preoperative chemotherapy in patients
with CLM has been recognized in recent years, and this
modality has become the standard treatment in the
United States and Europe [23,24]. Recently, Scilletta
et al. reported that neoadjuvant chemotherapy for CLM
is not a significant risk factor for surgical site infections
or complications according to the Clavien Dindo classi-
fication [25]. However, no study has investigated the
effect of perioperative chemotherapy on LLR, and there
remains a concern about the adverse effect of periopera-
tive chemotherapy-associated liver damage on LLR. In
this study, the perioperative chemotherapy group had a
drug-free period of >4 or >6 weeks after treatment with
mFOLFOX6 alone or with combination of bevacizumab,
respectively. Consequently, no adverse effects of chemo-
therapy on hepatic functional reserve were observed prior
to surgery; yet, gross and histological signs of hepatics with preoperative chemotherapy and those with
apy (n = 14) Surgery alone (n = 29) P value
23.8 ± 12.8 0.381
22.5 ± 15.2 0.207
0.67 ± 0.27 0.084
105.6 ± 16.1 0.331
20.4 ± 6.2 0.205
8.0 ± 3.8 0.424
4 (13.8%) 0.224
207.7 ± 271.3 0.111
7.4 ± 2.1 0.225
1 0.674
e green dye retention rate at 15 min; Plt, Platelet; PT, prothrombin
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Because management of bleeding is key to the comple-
tion of LLR, various energy devices and laparoscopic
equipment including a stapler are used to control bleed-
ing during liver tissue transection [26]. Intraoperative
bleeding is a concern in patients with sinusoidal dila-
tation; however, as in cirrhosis in hepatocellular car-
cinoma, bleeding can be controlled with appropriate
devices [7]. Accordingly, there were no differences in
blood loss, postoperative complications, or postopera-
tive hospital stay between the surgery alone and peri-
operative chemotherapy group in this study, failing to
show the adverse effect, if any, of chemotherapy on
LLR. In addition, rehepatectomy is often needed to treat
tumor recurrence in the remnant liver. Intra-abdominal
adhesions were relatively mild in patients treated with
LLR in the previous surgery, and even though LLR was
contraindicated in three of the patients on the basis of
tumor location, rehepatectomy by LLR was successfully
performed in the other three patients.
Conclusions
The present study demonstrates the minimal invasive-
ness of LLR for CLM and suggests that LLR is compar-
able with OR with regard to short-term prognosis. No
adverse effects of preoperative chemotherapy on LLR
were observed, and LLR appears to be a beneficial op-
tion for repeated liver resection for CLM. LLR is thus a
well-accepted surgical option for CLM, and chemotherapy
drugs can be used without adverse effects with the proper
knowledge of drug properties. However, to maximize the
efficacy of LLR, it is necessary to comply with the indica-
tions to ensure the curability and safety of patients, to per-
form detailed preoperative diagnostic imaging, and to use
the correct surgical devices.
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